Deep in the nucleus of an osteosarcoma cell, something impossible is happening: two regions of a chromosome that have remained separate throughout evolutionary history are touching, interacting, reshaping how the cell survives. Researchers at the University of Pittsburgh School of Medicine have discovered this unexpected genetic rearrangement in aggressive cancers, revealing a fundamental mechanism that allows tumors to divide indefinitely and evade treatment—a finding that could transform how doctors identify and track these dangerous cells.
The discovery centers on ALT-positive cancers, a subset representing 5–10% of all cancers, where tumor cells use an alternative lengthening of telomeres pathway to maintain chromosome ends without relying on telomerase, the enzyme most healthy cells employ. This clever cellular trickery allows cancer cells to keep dividing without the usual biological brakes. What researchers at UPMC Hillman Cancer Center have now uncovered is how these tumors pull off this trick: DNA sequences that normally belong at the centromere—the central anchor point of a chromosome—are being inserted near the telomere, the protective cap at the chromosome's end. These two regions were never supposed to interact.
"This is something that nobody expected," said Roderick O'Sullivan, senior author and professor in the Department of Pharmacology and Chemical Biology at Pitt. "These are two parts of the chromosome that are never supposed to interact." The finding, published in Nature, challenges a foundational assumption in cell biology that has held for decades: that the strict separation of these chromosome regions is essential to genome stability.
The researchers identified this pattern in both laboratory models and real patient tumors, including pediatric brain cancers, proving this is not a random cellular accident but a defining feature of ALT-positive cancers. In fact, ALT-positive tumors showed significantly higher levels of these mixed centromere-telomere DNA sequences than ALT-negative tumors, suggesting this chimeric DNA signature could serve as a biomarker to identify which tumors are driven by these unusual rearrangements and monitor how they evolve.
The mechanism depends on epigenetic changes—alterations in how DNA is packaged and regulated—particularly the loss of a protein called ATRX, which normally acts as a gatekeeper to keep centromere and telomere regions separated. When researchers disrupted this process in the lab, telomeres became unstable and ALT activity declined, suggesting this boundary-breaking interaction is critical to tumor survival. Yael Nechemia-Arbely, co-corresponding author and assistant professor at Pitt, notes the dark ingenuity at work: "It is remarkable that the illegitimate recombination between centromere and telomere sequences, which may begin as a mistake inside the cell, is actually being used by cancer cells to adapt and survive."
This discovery matters most for the hardest-to-treat cancers. ALT-positive tumors occur in pediatric neuroblastoma and other aggressive malignancies long associated with genomic instability and treatment resistance. Understanding the specific structural changes that enable ALT to function opens new possibilities: identifying these tumors earlier, potentially predicting their behavior, and perhaps developing therapies that exploit this unusual chromosomal dependency. For children and families facing these cancers, clarity about the enemy's strategy represents a crucial first step toward better weapons.